| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P356 | DOI | 10.1158/0008-5472.CAN-10-1296 |
| P8608 | Fatcat ID | release_jahnw3z3wzhafnwdch7et6v6kq |
| P932 | PMC publication ID | 4180868 |
| P698 | PubMed publication ID | 21159666 |
| P2093 | author name string | Ali R Jazirehi | |
| Benjamin Bonavida | |||
| James S Economou | |||
| Richard C Koya | |||
| Stavroula Baritaki | |||
| P2860 | cites work | Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 |
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| Tolerance, danger, and the extended family | Q29547532 | ||
| Regulation and function of NF-kappaB transcription factors in the immune system | Q29616427 | ||
| Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism | Q29619866 | ||
| Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. | Q31929631 | ||
| Antigen-processing machinery breakdown and tumor growth | Q34011098 | ||
| Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure | Q34335039 | ||
| How melanoma cells evade trail-induced apoptosis. | Q34572097 | ||
| IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis | Q34598755 | ||
| T-cell-receptor gene therapy | Q34718133 | ||
| Induction of antigen-specific T cell anergy: An early event in the course of tumor progression | Q35798927 | ||
| Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention | Q36079223 | ||
| Role of nuclear factor-kappa B in melanoma | Q36178379 | ||
| Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes | Q36327157 | ||
| Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy | Q36380506 | ||
| High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens | Q36471584 | ||
| Chemotherapy for metastatic melanoma: time for a change? | Q36698282 | ||
| Tumour cell survival signalling by the ERK1/2 pathway | Q37290943 | ||
| Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer | Q37326947 | ||
| Treatment combinations targeting apoptosis to improve immunotherapy of melanoma | Q37529471 | ||
| Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells | Q39269067 | ||
| The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack | Q39736061 | ||
| Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes | Q39752699 | ||
| NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways | Q39770370 | ||
| Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction | Q39820496 | ||
| Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death | Q39896920 | ||
| Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. | Q40022877 | ||
| Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins | Q40125495 | ||
| Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. | Q40174151 | ||
| Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription | Q42469738 | ||
| Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity | Q44615622 | ||
| Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies | Q44796666 | ||
| Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo | Q45880920 | ||
| Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. | Q46431069 | ||
| The role of Bcl-2 family members in the progression of cutaneous melanoma | Q47404782 | ||
| Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions | Q48048729 | ||
| Transfection of the CD8 gene enhances T-cell recognition. | Q53939368 | ||
| Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. | Q55239921 | ||
| Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction | Q59061007 | ||
| Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB | Q64381570 | ||
| Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity | Q73482871 | ||
| Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells | Q73526610 | ||
| Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma | Q73926153 | ||
| Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice | Q73937614 | ||
| Immunotherapy through TCR gene transfer | Q74569068 | ||
| Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma | Q80034682 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1406-1417 | |
| P577 | publication date | 2010-12-15 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction | |
| P478 | volume | 71 |
| Q37214957 | A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells |
| Q84351845 | A novel cytotoxic T lymphocyte epitope analogue with enhanced activity derived from cyclooxygenase-2 |
| Q37651094 | Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor |
| Q37519025 | Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants |
| Q34170130 | Advances in the study of HLA-restricted epitope vaccines |
| Q38720463 | Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells |
| Q53777162 | Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma. |
| Q38985389 | Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. |
| Q43916547 | Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment |
| Q85959217 | Current research on cell death mechanisms |
| Q36256459 | DNA vaccines, electroporation and their applications in cancer treatment |
| Q35589288 | Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway |
| Q34060387 | Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway |
| Q64978186 | How anti-PD1 treatments are changing the management of melanoma. |
| Q36256568 | MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model |
| Q27329598 | Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse |
| Q33869781 | New insights into the role of EMT in tumor immune escape. |
| Q37948056 | Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects |
| Q85942185 | Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials |
| Q36028423 | Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs |
| Q88442098 | Retraction: Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor-CTL Interaction |
| Q87988357 | Retraction: Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs |
| Q27671024 | TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms |
| Q33715943 | Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment. |
| Q33416734 | Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). |
Search more.